Harmony 6,7 Detailed Results in Tune with Mixed Top-Line Data
Detailed results from GlaxoSmithKline plc's Harmony 6 and Harmony 7 Phase III trials of albiglutide in Type II diabetes at 52 and 32 weeks presented at the American Diabetes Association Meeting in Philadelphia showed mixed results compared to positive top-line Harmony 6 results previously reported, and results consistent with a previously reported primary endpoint miss for Harmony 7.
Suite: 1100 | Atlanta, Georgia 30346, USA
Outside of the US
In the U.S. and Canada: +1-877-857-2477
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
Sign up for Highlights FREE e-mail newsletter